Why the study?
What are the reported events in patients who discontinue rivaroxaban therapy in response to legal advertising?
What are the reported events in patients who discontinue rivaroxaban therapy in response to legal advertising?
This review examines adverse events reported to Medwatch following the discontinuation of rivaroxaban prompted by legal advertising.
Patients may face adverse events after ad-prompted rivaroxaban stops; Level 5 data leave open advertising effects on adherence.
Rivaroxaban (XARELTO) is an oral Factor Xa inhibitor anticoagulant. Studied in over 85,000 patients,1 it was initially approved by the FDA in 2011 and is indicated to treat or prevent thrombosis in a variety of clinical settings; and when appropriately prescribed, for example in patients with atrial fibrillation, rivaroxaban has similar anticoagulant efficacy, with a lower risk of intracranial hemorrhage, as compared to the historical standard of warfarin.1
No takes yet. Share an insight, caveat, or question.
Burton et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: